BFC Planning’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
BFC Planning's SRPT Position: Q3 2026 in Review
BFC Planning held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 44 shares worth $802. The position accounts for ﹤0.01% of the portfolio, ranked #3206.
BFC Planning first reported a position in SRPT in Q3 2024 and has held it in 9 quarters since. The position peaked at $5.5K in Q3 2024. 228 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.
- BFC Planning held 44 shares of Sarepta Therapeutics worth $802 as of Q3 2026.
- BFC Planning left its Sarepta Therapeutics share count unchanged in Q3 2026.
- Sarepta Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3206 holding.
- BFC Planning first reported a position in Sarepta Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Sarepta Therapeutics position peaked at $5.5K in Q3 2024.
- 228 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.